Amphiphilic Matrix for Gimatecan Oral Absorption

Solution Overview

Problem

Camptothecin derivatives, such as 7-[(E)-t-butyloxyminomethyl]camptothecin (gimatecan), have limited solubility in water and variable absorption in the gastrointestinal tract, making it challenging to develop effective oral formulations with rapid release and improved bioavailability.

Innovation Solution

A pharmaceutical formulation using an amphiphilic matrix with tensioactive substances and co-solvents is developed, allowing for rapid solubilization and dispersion of the active principle in the gastrointestinal tract, enhancing bioavailability and absorption variability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If camptothecin derivatives are used for oral administration, then antitumoral activity is achieved, but solubility in water is limited and absorption variability is high

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent uses amphiphilic substances as intermediary carriers to solubilize the hydrophobic camptothecin derivative. These amphiphilic molecules have both hydrophilic and hydrophobic regions, allowing them to interact with both water and the drug molecule, thereby improving water solubility and absorption reliability without changing the active pharmaceutical ingredient itself.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the physical-chemical parameters of the formulation by adjusting the HLB value (hydrophile-lipophile balance) of the amphiphilic substance mixture. By optimizing this parameter, the formulation achieves optimal solubility and absorption characteristics for oral administration of the camptothecin derivative.

Inventive Principle:
Principle #35Parameter changes

2Speed

If immediate release formulation is developed, then absorption speed is improved, but formulation complexity increases

Engineering Contradiction:
Core Design Contradiction:
SpeedVSDevice complexity

Solution Approach 1:

The amphiphilic formulation system exhibits self-emulsifying properties upon contact with gastrointestinal fluids. The formulation automatically forms microemulsions without requiring external energy input or complex release mechanisms, achieving immediate release through self-service behavior that simplifies the overall formulation design.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent utilizes phase transition phenomena where the amphiphilic substances spontaneously form microemulsions when contacted with aqueous gastrointestinal fluids. This phase transition from a concentrated amphiphilic mixture to a dispersed microemulsion system enables rapid drug release and absorption without complex formulation mechanisms.

Inventive Principle:
Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation achieves rapid release and improved bioavailability of gimatecan, with over 80% release within 30 minutes in vitro, and reduced absorption variability, making it suitable for oral administration.

Implementation Method 1

A pharmaceutical formulation using an amphiphilic matrix with tensioactive substances and co-solvents is developed, allowing for rapid solubilization and dispersion of the active principle in the gastrointestinal tract

Methodology Applied
Scientific EffectMicelle formation: Emulsion

Implementation Method 2

A pharmaceutical formulation using an amphiphilic matrix with tensioactive substances and co-solvents is developed, allowing for rapid solubilization and dispersion of the active principle

Methodology Applied
Scientific EffectSurface tension reduction: Surfactant

Data Source

PatentEP1915153B1Immediate release therapeutic systems for improved oral absorption of 7-[(e)-tert-butyloxyiminomethyl]camtothecin
Publication Date: 2013.04.10

AI summary

A pharmaceutical composition comprising a camptothecin as active ingredient is herein described. In particular immediate-release therapeutic systems are described for the improved oral absorption of 7-[(E)-t-butyloxyminomethyl] camptothecin, comprising a matrix consisting of liquid amphiphilic substances or having a melting point lower than 60°C, in which the active principle is at least partially dissolved and/or dispersed and/or inglobated.